pan-serotype dengue virus NS4B inhibitor

oral preclin. candidate, trial planned

From 1.5M cmpd phenotypic screen + opt.

Sci. Transl. Med., Feb. 3, 2021

Novartis (NITD), Emeryville, CA

14. The Novartis pan-serotype dengue virus (DENV) NS4B protein inhibitor, NITD-688, is a preclinical candidate with strong activity against all four serotypes of DENV in vitro and excellent oral…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.